|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 22:03
|
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters′ Option to Purchase Additional Shares (GlobeNewswire EN)
|
|
|
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of common stock were sold at a price to the public of $5.00 per share and the pre-funded warrants were sold at a purchase price of $4.999 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics fr...
|
|
|
|
|
01.05.26 - 15:15
|
Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time (GlobeNewswire EN)
|
|
|
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026....
|
|
|
01.05.26 - 03:54
|
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80 million. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 2,400,0...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
